Literature DB >> 2953396

Plasminogen activator in normal subjects after exercise and venous occlusion: t-PA circulates as complexes with C1-inhibitor and PAI-1.

N A Booth, E Walker, R Maughan, B Bennett.   

Abstract

Exercise to exhaustion was associated with the appearance in plasma of plasminogen activator (PA) in several mol wt forms, as identified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with zymography. A number of active bands, all immunologically identified as tissue-type PA (t-PA), were observed. The major form had an apparent mol wt of approximately 60,000 and is due to free t-PA. The other strong bands had apparent mol wts of approximately 110,000 and 180,000. The 110,000 band, also present in pre-exercise samples, represents t-PA complexed with its major inhibitor (PAI-1), and the 180,000 band is due to t-PA complexed with C1 inhibitor. The released forms of t-PA were cleared rapidly after cessation of exercise at exhaustion. Urokinase-type PA (u-PA) activity was also identified in pre- and postexercise samples at an apparent mol wt of approximately 50,000. This is consistent with its being free u-PA; no complexed forms of u-PA were observed. Qualitatively similar changes in plasma PA were observed after venous occlusion. Small quantities of plasmin were generated after strenuous exercise, as observed by detection of plasmin-alpha 2-antiplasmin complex by two-dimensional immunoelectrophoresis in three of five subjects. This complex was cleared rapidly after cessation of exercise. Plasmin-alpha 2-antiplasmin complex was not detected in any of the subjects after venous occlusion.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2953396

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

1.  Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond.

Authors:  Angelo Agostoni; Emel Aygören-Pürsün; Karen E Binkley; Alvaro Blanch; Konrad Bork; Laurence Bouillet; Christoph Bucher; Anthony J Castaldo; Marco Cicardi; Alvin E Davis; Caterina De Carolis; Christian Drouet; Christiane Duponchel; Henriette Farkas; Kálmán Fáy; Béla Fekete; Bettina Fischer; Luigi Fontana; George Füst; Roberto Giacomelli; Albrecht Gröner; C Erik Hack; George Harmat; John Jakenfelds; Mathias Juers; Lajos Kalmár; Pál N Kaposi; István Karádi; Arianna Kitzinger; Tímea Kollár; Wolfhart Kreuz; Peter Lakatos; Hilary J Longhurst; Margarita Lopez-Trascasa; Inmaculada Martinez-Saguer; Nicole Monnier; István Nagy; Eva Németh; Erik Waage Nielsen; Jan H Nuijens; Caroline O'grady; Emanuela Pappalardo; Vincenzo Penna; Carlo Perricone; Roberto Perricone; Ursula Rauch; Olga Roche; Eva Rusicke; Peter J Späth; George Szendei; Edit Takács; Attila Tordai; Lennart Truedsson; Lilian Varga; Beáta Visy; Kayla Williams; Andrea Zanichelli; Lorenza Zingale
Journal:  J Allergy Clin Immunol       Date:  2004-09       Impact factor: 10.793

Review 2.  Fibrinolysis Shutdown in Trauma: Historical Review and Clinical Implications.

Authors:  Hunter B Moore; Ernest E Moore; Matthew D Neal; Forest R Sheppard; Lucy Z Kornblith; Dominik F Draxler; Mark Walsh; Robert L Medcalf; Mitch J Cohen; Bryan A Cotton; Scott G Thomas; Christine M Leeper; Barbara A Gaines; Angela Sauaia
Journal:  Anesth Analg       Date:  2019-09       Impact factor: 5.108

3.  Physical exercise modulates the level of serum MMP-2 and MMP-9 in patients with breast cancer.

Authors:  Maria Gabriella Giganti; Ilaria Tresoldi; Roberto Sorge; Giovanni Melchiorri; Tamara Triossi; Laura Masuelli; Paolo Lido; Loredana Albonici; Calogero Foti; Andrea Modesti; Roberto Bei
Journal:  Oncol Lett       Date:  2016-07-20       Impact factor: 2.967

4.  Shock-induced systemic hyperfibrinolysis is attenuated by plasma-first resuscitation.

Authors:  Hunter B Moore; Ernest E Moore; Alexander P Morton; Eduardo Gonzalez; Miguel Fragoso; Michael P Chapman; Monika Dzieciatkowska; Kirk C Hansen; Anirban Banerjee; Angela Sauaia; Christopher C Silliman
Journal:  J Trauma Acute Care Surg       Date:  2015-12       Impact factor: 3.313

Review 5.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

6.  Polyphosphate colocalizes with factor XII on platelet-bound fibrin and augments its plasminogen activator activity.

Authors:  Joanne L Mitchell; Ausra S Lionikiene; Georgi Georgiev; Anja Klemmer; Chelsea Brain; Paul Y Kim; Nicola J Mutch
Journal:  Blood       Date:  2016-09-30       Impact factor: 22.113

7.  A mutation unique in serine protease inhibitors (serpins) identified in a family with type II hereditary angioneurotic edema.

Authors:  J G Ocejo-Vinyals; F Leyva-Cobián; J L Fernández-Luna
Journal:  Mol Med       Date:  1995-09       Impact factor: 6.354

8.  Tissue plasminogen activator, plasminogen activator inhibitor, and other parameters of fibrinolysis in the early stages of taurocholate acute pancreatitis in rats.

Authors:  G Rydzewska; S Kosidlo; A Gabryelewicz; A Rydzewski
Journal:  Int J Pancreatol       Date:  1992-06

9.  Fibrinolysis shutdown is associated with a fivefold increase in mortality in trauma patients lacking hypersensitivity to tissue plasminogen activator.

Authors:  Hunter B Moore; Ernest E Moore; Benjamin R Huebner; Monika Dzieciatkowska; Gregory R Stettler; Geoffrey R Nunns; Peter J Lawson; Arsen Ghasabyan; James Chandler; Anirban Banerjee; Christopher Silliman; Angela Sauaia; Kirk C Hansen
Journal:  J Trauma Acute Care Surg       Date:  2017-12       Impact factor: 3.313

Review 10.  Thrombolysis in the management of acute myocardial infarction and unstable angina pectoris.

Authors:  J Loscalzo
Journal:  Drugs       Date:  1989-02       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.